 |  |  |  |  |  |  |  |  |  |
SEARCH:
Sponsored by:
|
Head & Neck
|
|
|
Hamid Mirshahidi, MDLoma Linda University School of Medicine, Loma Linda, CA Medullary thyroid cancer (MTC) is a rare but aggressive disease. Unfortunately, there is not an effective conventional chemotherapy regimen for the disease. New strategies to treat metastatic MTC, including... »
Community Translations
Community Translations Commentary Promising data, but challenges remain in selecting appropriate TKIs
Hamid Mirshahidi, MDLoma Linda University School of Medicine, Loma Linda, CA Medullary thyroid cancer (MTC) is a rare but aggressive disease. Unfortunately, there is not an effective conventional chemotherapy regimen for... »
COMMUNITY TRANSLATIONS Vandetanib in advanced hereditary medullary thyroid cancer
Report prepared by Matt Stenger, MS Medullary thyroid cancer (MTC), the third most common type of thyroid cancer, presents in a sporadic form in about 75% of cases and in a hereditary form in about 25%. Ten-year survival in... »
Hamid Mirshahidi, MDLoma Linda University School of Medicine, Loma Linda, CA Medullary thyroid cancer (MTC) is a rare but aggressive disease. Unfortunately, there is not an effective conventional chemotherapy regimen for... »
COMMUNITY TRANSLATIONS Vandetanib in advanced hereditary medullary thyroid cancer
Report prepared by Matt Stenger, MS Medullary thyroid cancer (MTC), the third most common type of thyroid cancer, presents in a sporadic form in about 75% of cases and in a hereditary form in about 25%. Ten-year survival in... »
Current Issue
Community Oncology
Concentrates on original research,
rare cancers, quality of care in
community oncology, and practice guidelines. »
Latest Supplement
Highlights of the 6th Annual Community Oncology Conference. »
For past issues, click here »
calendar
More Calendar »